AVN944 inhibits IMPDH and induces apoptosis-related biomarkers in patients with hematologic cancers

vated even in the absence of circulating levels of the drug between doses. Other genes directly related to IMPDH inhibition showed similar response characteristics.

"AvalonRx, our proprietary gene expression platform, enabled us to identify a set of 34 genes that reflect the mechanism-based activity of AVN944," said David Bol, Ph.D., Senior Vice President of Product and Pharmaceutical Development at Avalon. "These gene markers correlate with the biochemical effects of AVN944 on protein function, which we believe will result in tumor cell apoptosis at the right doses. Our goal for the current Phase I study is to achieve those dose levels in patients. It is very encouraging that we have not seen any drug related adverse events even though we are already seeing biomarker movements consistent with significant inhibition of the IMPDH enzyme. This indicates the potential for a good therapeutic window. Additionally, these data showcase the power of the AvalonRx technology in understanding the pharmacologic, pharmacodynamic and biologic activity of a drug on patients in early clinical studies."

This analysis of the trial data was intended to describe how these biomarkers correlate with biologic activity of the drug in patients as the doses escalate. When comparing patients with different hematologic cancers, examination of the complete set of markers clearly demonstrated the utility of comprehensive gene expression analysis in clinical trials by distinguishing individuals with similar diseases, as well as patients with different malignancies, based on the makeup of their disease prior to drug administration as well as the different nature of the cellular response following drug administration.


Contact: Wendy Lau
Euro RSCG Life NRP

Page: 1 2

Related biology news :

1. Gene therapy inhibits epilepsy in animals
2. Antibiotic inhibits cancer gene activity
3. Unusual three-drug combo inhibits growth of aggressive tumors
4. Activation of microRNA inhibits cancer gene in human cancer cells
5. Dartmouth study finds that arsenic inhibits DNA repair
6. Viral hitchhiker inhibits Wolbachia bacterias ability to proliferate
7. Food additive inhibits longevity enzyme in yeast, increases cell toxicity, new study finds
8. VCU Massey Cancer Center researchers find new agent inhibits Leukemia cell survival
9. Antibody to a naturally-occurring sugar chain in colon inhibits inflammatory bowel disease
10. Researchers find molecule that inhibits regrowth of spinal nerve cells
11. Compound inhibits one critical pathway in breast cancer growth

Post Your Comments:

(Date:5/30/2020)... , ... May 29, 2020 , ... ... digital transformation for enterprises globally, has collaborated with EchoNous Inc. to develop the ... It can measure systolic heart function, which has been clinically tested versus expert ...
(Date:5/28/2020)... ... May 28, 2020 , ... Actuate Therapeutics, ... their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) will be presented at ... place virtually on May 29th, 2020. Dr. Benedito Carneiro, Brown University’s principal investigator ...
(Date:5/21/2020)... (PRWEB) , ... May 19, ... ... the leading software-as-a-service (SaaS) provider of operations management solutions, today introduced BioMed ... module provides a cloud-based platform for connecting the people and systems around ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... ... June 30, 2020 , ... ... that the launch of a new clinical diagnostics immuno-oncology service, TissueInsight ... microenvironment (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... solutions providers, today announced its strong opposition to the recently introduced bicameral ... a blanket ban on most federal use of nearly all biometric and related ...
(Date:6/23/2020)... , ... June 22, 2020 , ... ... glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association for ... DRP-104; and, the other profiles the potent, consistent single agent activity in KEAP1 ...
(Date:6/11/2020)... ... June 09, 2020 , ... ... of a Small Business Innovation Research (SBIR) program funded by the National Institute ... Toxin Detection in the Field”. The project’s goal was to engineer and develop ...
Breaking Biology Technology:
Cached News: